Barclays lowered the firm’s price target on Exscientia to $9 from $10 and keeps an Overweight rating on the shares. The analyst updated the firm’s model following Exscientia’ acquisition of full rights to the CDK7 program from GT Apeiron.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAI:
- Exscientia Secures Full Rights to Novel Cancer Drug
- Exscientia pays GT Apeiron $10M upfont cash+ equity for ‘full control’ of 617
- Exscientia launches AWS AI-powered platform to advance drug discovery
- Exscientia initiated with a Buy at TD Cowen
- Class Action Lawsuit against Exscientia PLC (NASDAQ:EXAI)